Candesartan Trityl methyl ester impurity

Candesartan Trityl methyl ester impurity is a synthetic byproduct formed via tritylation of the parent drug's bicyclic core, substituting the sulfonamide group with a trisubstituted benzyl ester. The trityl moiety comprises three fused aromatic rings conjugated to a methyl-esterified carbon, inducing steric hindrance and reduced pharmacophore activity. This impurity arises during Candesartan synthesis due to competing esterification pathways, retaining the dihydropyridine scaffold but lacking angiotensin II receptor antagonism. It functions as a reference standard for HPLC-based quantification of process-derived impurities in Candesartan formulations.